1. Home
  2. RYI vs MLYS Comparison

RYI vs MLYS Comparison

Compare RYI & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RYI
  • MLYS
  • Stock Information
  • Founded
  • RYI 1842
  • MLYS 2019
  • Country
  • RYI United States
  • MLYS United States
  • Employees
  • RYI N/A
  • MLYS N/A
  • Industry
  • RYI Metal Fabrications
  • MLYS Biotechnology: Pharmaceutical Preparations
  • Sector
  • RYI Industrials
  • MLYS Health Care
  • Exchange
  • RYI Nasdaq
  • MLYS Nasdaq
  • Market Cap
  • RYI 661.1M
  • MLYS 634.6M
  • IPO Year
  • RYI N/A
  • MLYS 2023
  • Fundamental
  • Price
  • RYI $20.22
  • MLYS $10.39
  • Analyst Decision
  • RYI Hold
  • MLYS Strong Buy
  • Analyst Count
  • RYI 1
  • MLYS 2
  • Target Price
  • RYI $28.00
  • MLYS $30.00
  • AVG Volume (30 Days)
  • RYI 270.1K
  • MLYS 266.6K
  • Earning Date
  • RYI 02-19-2025
  • MLYS 11-11-2024
  • Dividend Yield
  • RYI 3.63%
  • MLYS N/A
  • EPS Growth
  • RYI N/A
  • MLYS N/A
  • EPS
  • RYI 0.64
  • MLYS N/A
  • Revenue
  • RYI $4,703,700,000.00
  • MLYS N/A
  • Revenue This Year
  • RYI N/A
  • MLYS N/A
  • Revenue Next Year
  • RYI $1.76
  • MLYS N/A
  • P/E Ratio
  • RYI $32.51
  • MLYS N/A
  • Revenue Growth
  • RYI N/A
  • MLYS N/A
  • 52 Week Low
  • RYI $17.18
  • MLYS $8.58
  • 52 Week High
  • RYI $36.15
  • MLYS $16.91
  • Technical
  • Relative Strength Index (RSI)
  • RYI 54.54
  • MLYS 38.31
  • Support Level
  • RYI $20.56
  • MLYS $9.18
  • Resistance Level
  • RYI $21.15
  • MLYS $9.97
  • Average True Range (ATR)
  • RYI 0.70
  • MLYS 0.81
  • MACD
  • RYI 0.46
  • MLYS -0.19
  • Stochastic Oscillator
  • RYI 89.92
  • MLYS 26.21

About RYI Ryerson Holding Corporation

Ryerson Holding Corp provides a metals service center, and value-added processor and is a distributor of industrial metals with operations in the United States, Canada, and Mexico. In addition to its North American operations, it conducts processing and distribution operations in China. Its customers range from local, independently owned fabricators and machine shops to large, international original equipment manufacturers. It carries a full line of products in stainless steel, aluminum, carbon steel, and alloy steels and a limited line of nickel and red metals in various shapes and forms. The company generates substantially all of its revenue from sales of metal products. Geographically, the majority is from the United States.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.

Share on Social Networks: